Table 31: Patient Characteristics: Holmium Laser Enucleation of the Prostate Versus TURP.
| Study, Year | Patients, No. (Treatment, control) | Inclusion criteria | Prostate size Mean (SD), mL | Mean follow-up Years (months where specified) | No. available for follow-up |
|---|---|---|---|---|---|
| Rigatti et al. 2006 (72) | 100 (52, 48) |
Patients with BPH younger than 72 years; prostate size 30–100 gr; Qmax <15 mL/s; PVR <100 mL, medical therapy failure; Schafer >2; obstruction on the International Continence Society nomogram, and Abram-Griffiths >40 | HoLEP: 60.3 (36.7) TURP: 56.2 (19.4) P =.05 |
1 | All |
| Gupta et al. 2006 (55) 3-arm study |
100 (50, 50) Plus 50 patients in TUVRP group |
Patients with BPH who were candidates for TURP and gland size of >40 g | HoLEP: 57.9 (17.6) TURP: 59.8 (16.5) |
1 | NR |
| Kuntz et al. 2004 (39) | 200 (100, 100) |
Patients with BPH who had AUA symptom score ≥12; Qmax ≤12mL/s; PVR>50mL; Schafer grade ≥ 2; Prostate volume <100 cc | HoLEP: 53.5 (20.0) TURP: 49.9 (21.1) |
1 | HoLEP: 89 TURP: 86 (13 patients with incidental carcinoma and 8 who developed stricture were excluded from analysis) |
| Tan et al. 2003 (40) | 61 (31, 30) |
Patients with BPH who had prostate volume 40–200 mL; Qmax </=15 mL/s; AUA score >/=8; PVR <400 mL; Schafer grade ≥2 | HoLEP: 77.8 (5.6) TURP: 70.0 (5.0) |
1 | HoLEP: 25 TURP: 27 |
AUA refers to American Urological Association; BPH, benign prostatic hyperplasia; HoLEP, holmium laser enucleation of the prostate; NR, not reported; PVR, postvoid residual; Qmax, maximum flow rate; TURP, transurethral resection of the prostate